Announcement on Provision for Asset Impairment in 2024
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Provision for Asset Impairment in 2024
Filed with SSE ·
6ix hasn’t read this filing yet.
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on Change of Sponsor Institution and Sponsor Representative
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment
- Announcement on Obtaining Government Subsidy
Later from Chengdu Olymvax Biopharmaceuticals
- Announcement on Convening 2024 Annual Performance and Cash Dividend Briefing
- Announcement on Resolutions of 2024 Annual General Meeting
- Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and the Q1 2025 Performance Briefing
- Indicative Announcement on Postponing Term Change of Board of Directors and Board of Supervisors and Expiration of Term of Independent Director
- Announcement on Release of Pledge of Some Shares Held by Shareholders with Over 5% Shares
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals